MedTrace Logo

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

NCT00807196 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-12-11

No results posted yet for this study

Summary

The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.

Conditions

  • Non-Hodgkins Lymphoma

Interventions

DRUG

Rituximab

250mg/m2 day -21 and day -14 of preparative regimen

DRUG

90Y ibritumomab tiuxetan (Zevalin)

0.4 mCi/kg IV on day -14 of preparative regimen

DRUG

Cyclophosphamide

300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen

DRUG

Fludarabine

30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen

OTHER

Non myeloablative allogeneic stem cell transplantation

Blood stem cell infusion on day 0

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Maisonneuve-Rosemont Hospital

    lead OTHER

Principal Investigators

  • Thomas Kiss, MD · Maisonneuve-Rosemont Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-12-31
Completion
2012-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00807196 on ClinicalTrials.gov